Previous 10 | Next 10 |
2023-03-29 13:26:31 ET Summary 23andMe is known around the world for its ancestry DNA genetic testing service. The company's pivot into therapeutics seems attractive. But the company saw revenue decrease from $441 million in 2019 to $272 in 2022. What's the value of having...
2023-03-29 07:56:11 ET Summary GeneDx Holdings Corp. has had a dreadful performance as a stock. GeneDx's number of shares outstanding have absolutely exploded. GeneDx has a negative gross margin and is significantly burning cash. While its business model has merit, you nee...
23andMe Publishes Inaugural Environmental, Social and Governance Report PR Newswire ESG report outlines strategic framework and current initiatives for ensuring ethical management, promoting a diverse and equitable culture, and implementing sustainable operations SOU...
SOUTH SAN FRANCISCO, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- In support of Lipoprotein(a) Awareness Day, 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, today announced a collaboration with Novartis Pharmaceuticals Corporation (Novartis) to i...
92 percent of doctors in the U.S. say genetics is an important part of a patient’s complete health picture 66 percent of doctors say genetic testing could help lead to better outcomes for their patients 75 percent of people in the US said they’d be more likely to fol...
Toronto, Ontario--(Newsfile Corp. - March 2, 2023) - Moneta Gold Inc. (TSX: ME) (OTCQX: MEAUF) (FSE: MOPA) ("Moneta" or the "Company") is pleased to announce the assay results from forty-three (43) resource infill and step-out drill holes on the 903 gold deposit at the Tower Gold project (the...
Summary 23andMe has made many strategic acquisitions that have helped the company expand and grow. The genomics industry as a whole is expected to have rapid growth in the future due to the convenience of testing kits as well as the decreased prices. ME stock has invested a lot into...
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2023 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company, with a mission to help people access, understand and benefit from the human genome, dosed the first patient in the Phase 2a portion of...
Summary 23andMe continues to burn cash with no clear path to profitability in the near term. 23andMe has launched new products and services, but the impact on its financial performance has yet to be seen. Economic risks and dilution of shareholder value are additional concerns. ...
Toronto, Ontario--(Newsfile Corp. - February 15, 2023) - Moneta Gold Inc. (TSX: ME) (OTCQX: MEAUF) (FSE: MOPA) ("Moneta") is pleased to announce assay results from thirty (30) resource infill and step-out drill holes on the 903 gold deposit at the Tower Gold project (the "Project"), located in ...
News, Short Squeeze, Breakout and More Instantly...
SOUTH SAN FRANCISCO, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME) (23andMe), a leading human genetics and biopharmaceutical company with a mission to help people access, understand, and benefit from the human genome, announced today that it will report financial resu...
SUNNYVALE, Calif., July 25, 2024 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (Nasdaq: ME), a leading genetic health and biopharmaceutical company, in collaboration with 20 lung cancer advocacy organizations, today announced a new study to help advance research in lung cancer. The focus of the Lun...